Fragment-based drug design screens a library of small molecular fragments for target binding, then elaborates successful fragments into stronger lead compounds. Unlike conventional screening, fragments probe binding-site structure extensively despite using a smaller library. section 7.3 section 7.3.1
A practical fragment-based workflow includes:
- Screen a fragment library and identify multiple fragments with measurable affinity for the target. section 7.3
- Grow one fragment by adding R-groups; rigid additions are generally preferred because flexible groups can make affinity and interpretation less predictable. section 7.3.1
- Link two non-competitive fragments occupying different sub-pockets, while computing a linker orientation that balances connection and conformational freedom. section 7.3.1
- Merge fragments that partially occupy the same region into one structure combining useful portions of both. section 7.3.1
- Optimize the expanded compound and verify that its binding profile improves over the individual fragments; many resulting compounds will not become suitable leads. section 7.3.1
Fragments are weak binders, and measured binding may reflect a crystallized, static protein structure. Consequently, expansion, linking, or merging does not guarantee improved affinity or a viable lead. section 7.3.1
